PDF Viewer

BUILDER'S SANDBOX

Build This Paper

Use an AI coding agent to implement this research.

OpenAI Codex
OpenAI CodexAI Agent

Lightweight coding agent in your terminal.

Claude Code
Claude CodeAI Agent

Agentic coding tool for terminal workflows.

AntiGravity IDE
AntiGravity IDEScaffolding

AI agent mindset installer and workflow scaffolder.

Cursor
CursorIDE

AI-first code editor built on VS Code.

VS Code
VS CodeIDE

Free, open-source editor by Microsoft.

MVP Investment

$10K - $13K
6-10 weeks
Engineering
$8,000
Cloud Hosting
$240
SaaS Stack
$800
Domain & Legal
$500

6mo ROI

2-4x

3yr ROI

10-20x

Lightweight AI tools can reach profitability quickly. At $500/mo average contract, 20 customers = $10K MRR by 6mo, 200+ by 3yr.

Talent Scout

J

Justyna Andrys-Olek

Sano Centre for Computational Personalised Medicine, Krakow, Poland

P

Paulina Tworek

Sano Centre for Computational Personalised Medicine, Krakow, Poland

L

Luca Gherardini

Sano Centre for Computational Personalised Medicine, Krakow, Poland

M

Mark W. Ruddock

Randox Laboratories Ltd., Co., Antrim, United Kingdom

Find Similar Experts

AI experts on LinkedIn & GitHub

References (49)

[1]
Stability of Machine Learning Predictive Features Under Limited Data
2025Karol Capała, Paulina Tworek et al.
[2]
Not someone, but something: Rethinking trust in the age of medical AI
2025Jan Beger
[3]
Evaluation of six novel biomarkers for predicting recurrence of non-muscle invasive bladder cancer after endoscopic resection– a prospective observational study
2025K. Bardowska, Wojciech Krajewski et al.
[4]
Clusterin: structure, function and roles in disease
2025Xing Du, Zhongyao Chen et al.
[5]
The role of IL-8 in cancer development and its impact on immunotherapy resistance.
2025Clara Meier, A. Brieger
[6]
Innovation and challenges of artificial intelligence technology in personalized healthcare
2024Yu-Hao Li, YuLin Li et al.
[7]
Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1
2024A. Ibrahim, T. Fujimura et al.
[8]
Urinary IL‐6 and IL‐8 as predictive markers in bladder urothelial carcinoma: A pilot study
2023C. VandenBussche, C. D. Heaney et al.
[9]
CACTUS: A Comprehensive Abstraction and Classification Tool for Uncovering Structures
2023L. Gherardini, Varun Varma et al.
[10]
Albuminuria and the risk of cancer: the Stockholm CREAtinine Measurements (SCREAM) project
2023Li Luo, Yuanhang Yang et al.
[11]
An Overview of Angiogenesis in Bladder Cancer
2023Ghada Elayat, Ivan Punev et al.
[12]
Explainable Artificial Intelligence (XAI): What we know and what is left to attain Trustworthy Artificial Intelligence
2023Sajid Ali, Tamer Abuhmed et al.
[13]
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF.
2023S. Ghalehbandi, J. Yuzugulen et al.
[14]
Handling Missing Data in Clinical Research.
2022M. Heymans, J. Twisk
[15]
PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity
2022H. Furuya, Y. Sasaki et al.
[16]
Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers
2022Jae-Hak Ahn, Chan-Koo Kang et al.
[17]
Trustworthy Artificial Intelligence: A Review
2022Davinder Kaur, Suleyman Uslu et al.
[18]
Sustained postoperative plasma elevations of plasminogen activator inhibitor-1 following minimally invasive colorectal cancer resection
2021H. S. Kumara, Poppy Addison et al.
[19]
Diagnostic performance of Midkine ratios in fine-needle aspirates for evaluation of Cytologically indeterminate thyroid nodules
2021Le Zhou, Jinxi Jiang et al.
[20]
Hematuria in Adults.
2021J. Ingelfinger

Showing 20 of 49 references

Founder's Pitch

"Develop a robust and interpretable machine learning framework for handling incomplete clinical data in medical decision-making."

AI in HealthcareScore: 7View PDF ↗

Commercial Viability Breakdown

0-10 scale

High Potential

1/4 signals

2.5

Quick Build

4/4 signals

10

Series A Potential

3/4 signals

7.5

Sources used for this analysis

arXiv Paper

Full-text PDF analysis of the research paper

GitHub Repository

Code availability, stars, and contributor activity

Citation Network

Semantic Scholar citations and co-citation patterns

Community Predictions

Crowd-sourced unicorn probability assessments

Analysis model: GPT-4o · Last scored: 2/19/2026

🔭 Research Neighborhood

Generating constellation...

~3-8 seconds

Why It Matters

This research addresses the critical need for trustworthy machine learning tools that can handle incomplete and biased datasets in high-stakes healthcare environments, such as clinical decision-making, where data completeness cannot always be guaranteed.

Product Angle

The product can be developed into a tool or API that integrates with existing medical record systems, providing insights and decision support to healthcare professionals without the need for a complete dataset.

Disruption

It could replace traditional statistical decision-support systems in healthcare that do not handle missing data well or provide interpretable results.

Product Opportunity

The health AI market is large and driven by the need for more reliable diagnostic tools. Hospitals and healthcare providers seeking solutions to reduce diagnostic errors and improve decision-making under imperfect data scenarios would be key buyers.

Use Case Idea

Develop a clinical decision support tool for healthcare providers to use in diagnostic processes, particularly beneficial in scenarios where patient data may be incomplete or missing.

Science

The framework, named CACTUS, focuses on maintaining feature stability under data perturbations by using techniques like feature abstraction and interpretable classification. It quantifies how well informative features are preserved when data quality is compromised, providing an edge over traditional models which typically focus only on accuracy.

Method & Eval

CACTUS was tested on a real-world medical cohort to classify bladder cancer versus non-cancer patients, showing superior feature stability under different levels of artificially introduced missing data compared to existing models like random forests and gradient boosting.

Caveats

The paper doesn't mention a publicly available codebase or dataset, which limits immediate replication of results. Furthermore, real-world integration into clinical settings may face adoption barriers due to regulatory and data privacy concerns.

Author Intelligence

Justyna Andrys-Olek

Sano Centre for Computational Personalised Medicine, Krakow, Poland
j.andrys-olek@sanoscience.org

Paulina Tworek

Sano Centre for Computational Personalised Medicine, Krakow, Poland
p.tworek@sanoscience.org

Luca Gherardini

Sano Centre for Computational Personalised Medicine, Krakow, Poland

Mark W. Ruddock

Randox Laboratories Ltd., Co., Antrim, United Kingdom

Mary Jo Kurt

Coimbra University, Multidisciplinary Institute of Ageing, MIA - Portugal, Coimbra, Portugal

Peter Fitzgerald

Randox Laboratories Ltd., Co., Antrim, United Kingdom

Jose Sousa

Sano Centre for Computational Personalised Medicine, Krakow, Poland; Randox Laboratories Ltd., Co., Antrim, United Kingdom
j.sousa@sanoscience.org